Compare Bank of New York Mellon Corp (BNY) vs Quest Diagnostics Inc (DGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bank of New York Mellon Corp vs Quest Diagnostics Inc — how do they compare? Bank of New York Mellon Corp trades at $162.9 (market cap $108.78B), while Quest Diagnostics Inc trades at $237.51 (market cap $26.21B). The key difference: Bank of New York Mellon Corp is far larger — about 4.2× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays the higher dividend (1.45%). Which is the better fit depends on your goals.
| BNY | DGX | |
|---|---|---|
Market Cap | $108.78B | $26.21B |
Sector | Financials | Health |
52-Week High | $162.35 | $238.50 |
52-Week Low | $101.00 | $173.49 |
Dividend Yield | 1.38% | 1.45% |
Enterprise Value | — | $31.97B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNY stock trades at $162.98, up 2.22% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported record Q2 2026 results with EPS of $2.46, surpassing estimates, and announced a strategic collaboration to advance digital asset infrastructure. Revenue growth is steady, rising to $19.76B in 2025, with a net income margin of 29.96%.
Outlook remains positive with a consensus price target of $170.36, though risks include high investing cash outflows and competitive pressures. The stock's current price is near the consensus target, suggesting limited upside without further catalysts. Institutional sentiment is mixed, with 45% buy ratings and 55% hold.
Quest Diagnostics (DGX) trades at $237.99, up 0.15% on the day, near its 52-week high. The stock shows strong momentum with consecutive earnings beats in 2026, including Q2 EPS of $3.12 versus $2.82 expected. Revenue growth accelerated to $11.04 billion in 2025, with net income margin at 9.19%. Technical indicators signal a bullish trend, while analyst consensus is a $249.50 price target. Recent news highlights AI integration and raised 2026 outlook amid robust testing demand.
The outlook for DGX is positive, driven by earnings momentum, strategic partnerships, and healthcare demand. Investment opportunity lies in sustained growth and dividend yield, but risks include margin pressure from lower-margin deals and high debt levels. Valuation at a P/E of 25.21 requires continued execution to justify upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bank of New York Mellon Corp
BNY Mellon is a global investment company involved in managing and servicing financial assets throughout the investment lifecycle. The bank provides financial services for institutions, corporations, and individual investors and delivers investment management and investment services in 35 countries and more than 100 markets. BNY Mellon is the largest global custody bank in the world, with about $41.1 trillion in under custody and administration (as of Dec. 31, 2020), and can act as a single point of contact for clients looking to create, trade, hold, manage, service, distribute, or restructure investments. BNY Mellon's asset-management division manages about $2.2 trillion in assets.
Read more on BNY →About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →
